Health­Care Roy­al­ty pays Atara $31M cash for a piece of cell ther­a­py roy­al­ties in Eu­rope

Health­Care Roy­al­ty has joined Atara Bio­ther­a­peu­tics and Pierre Fab­re in bet­ting on the promise of Ebval­lo, Atara’s first ap­proved drug that’s used to treat a com­pli­ca­tion af­ter or­gan trans­plants.

The firm will pay Atara a $31 mil­lion up­front pay­ment as part of a roy­al­ty in­ter­est fi­nanc­ing agree­ment to have a piece of Ebval­lo in Eu­rope and oth­er re­gions in­clud­ed in a com­mer­cial­iza­tion and mar­ket­ing deal Atara penned with Pierre Fab­re in Oc­to­ber last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER